5769-13-1

Basic information

• Product Name: trans-4-phenylcyclohexan-1-ol
• Synonyms: trans-4-phenylcyclohexan-1-ol;trans-4-Phenylcyclohexanol;(1α)-4β-Phenylcyclohexanol;(1α,4β)-4-Phenylcyclohexanol;YVVUSIMLVPJXMY-HAQNSBGRSA-N;Cyclohexanol, 4-phenyl-, trans-
• CAS NO: 5769-13-1
• Molecular Formula: C₁₂H₁₆O
• Molecular Weight: 176.25484
• EINECS: 227-295-0
• Mol File: 5769-13-1.mol
• Article Data: 87

Chemical Properties

• Boiling Point: 295.8°Cat760mmHg
• Flash Point: 113.3°C
• Appearance: /
• Density: 1.051g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: -20°C Freezer
• Solubility: DCM, Ethyl Acetate
• CAS DataBase Reference: trans-4-phenylcyclohexan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-phenylcyclohexan-1-ol(5769-13-1)
• EPA Substance Registry System: trans-4-phenylcyclohexan-1-ol(5769-13-1)

Safety Data

• Hazardous Substances Data: 5769-13-1(Hazardous Substances Data)

Usage

Description

Trans-4-phenylcyclohexan-1-ol, also known as trans-4-phenylcyclohexanol, is an organic compound with the molecular formula C12H16O. It features a cyclohexane ring with a phenyl group attached to the fourth carbon and a hydroxyl group attached to the first carbon. trans-4-phenylcyclohexan-1-ol is known for its potential applications in various industries due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
Trans-4-phenylcyclohexan-1-ol is used as an intermediate in the synthesis of Atovaquone derivatives (A793500) for the pharmaceutical industry. Atovaquone is a broad-spectrum antiprotozoal medication used to treat or prevent Pneumocystis jirovecii pneumonia (PCP) and malaria. trans-4-phenylcyclohexan-1-ol's role as an intermediate in the synthesis of these derivatives highlights its importance in the development of life-saving medications.

InChI:InChI=1/C12H16O/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-5,11-13H,6-9H2/t11-,12-

Upstream product

• 64-19-7 acetic acid 
• 92-69-3 4-Phenylphenol 
• 5769-13-1 4-phenyl-cyclohexanol 
• 827-52-1 1-phenyl-1-cyclohexane 
• 7335-12-8 cis-4-phenylcyclohexanol 
• 1220688-55-0 C₃₃H₃₅NO 
• 1444-65-1 (RS)-2-phenylcyclohexanone 
• 4894-75-1 1-phenyl-4-cyclohexanone 
• 1466-74-6 4‐phenylcyclohexan‐1‐carbaldehyde 
• 29538-77-0 trans-4-hydroxycyclohexyl chloride 
• 100-59-4 phenylmagnesium chloride 
• 1093198-53-8 C₂₈H₂₆O₃ 
• 1079-68-1 (+/-)-trans-2-bromo-4-phenyl-cyclohexanone 
• 91909-96-5 5-Phenylcyclohexan-2-on-carbonsaeure-⁽¹⁾ 

Downstream Products

• 4894-75-1 1-phenyl-4-cyclohexanone 
• 42367-12-4 cis-4-phenyl-1-bromocyclohexane 
• 19992-45-1 cis-4-phenylcyclohexylamine 
• 5437-46-7 trans-4-phenylcyclohexanol 
• 250293-45-9 4-Phenylcyclohexanone N-phenylhydrazone 
• 1093198-53-8 C₂₈H₂₆O₃ 
• 199383-82-9 4-phenyl-1-cyclohexen-1-ol acetate 
• 4994-16-5 4-phenylcyclohexene 
• 95157-05-4 4-phenyl-cyclohexanone-(2,4-dinitro-phenylhydrazone) 
• 4500-20-3 4-phenylcyclohexanone oxime 
• 180295-25-4 trans-2-(4-Phenylcyclohexyloxy)tetrahydropyran 

Relevant articles and documents

Site-Selective Synthesis of Aryl Sulfides via Oxidative Aromatization of Cyclohexanones with Thiophenols

We have introduced a metal-free facile access for the thiolation/aromatization of cyclohexanones with thiophenols to the corresponding aryl sulfides. The dehydroaromatic reaction of non-aromatic cyclohexanones proceeded smoothly using oxygen as a green oxidant.

PNO ligand containing planar chiral ferrocene and application thereof

The invention discloses a PNO ligand containing planar chiral ferrocene and application thereof. The PNO ligand containing planar chiral ferrocene is a planar chiral ferrocene-containing and phenol-containing PNO ligand as shown in a general formula (I) or (II) which is described in the specification, or a planar chiral ferrocene-containing and aryl-phosphoric-acid-containingPNO ligand containing as shown in a general formula (III) or (IV) which is described in the specification, or a planar chiral ferrocene-containing and carbon-chiral-phenol-containingPNO ligand as shown in a general formula (V) or (VI) which is described in the specification. The invention provides tridentate PNO ligands and processes for their complexation with transition metal salts or transition metal complexes; the introduction of salicylaldehyde and derivatives thereof, which are simple and easy to obtain, enables the ligands to have a bifunctionalization effect, and -OH in a formed catalyst has stronger acidity and is beneficial to combination with N/O in polar double bonds. Therefore, due to the bifunctionalization effect of the catalyst, the interaction between the catalyst and a substrate can be greatly improved, so a reaction can obtain higher catalytic activity and stereoselectivity.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.